PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes                 Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines Agency approvalCompany has 12 years’ worth of safety...

PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 yearsA proportion of patients remained insulin-independent for up to 24 monthsPTG-007 ready to enter pivotal studyData...

PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy                Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes               Gdańsk, Poland – 16 January 2024, 07:00 CET – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide...